您的购物车当前为空
GLP-1(32-36)amide 是由胰高血糖素样肽-1(GLP-1)衍生而来的五肽片段,序列为 LVKGR amide。在高血糖钳夹实验中,以 30 pmol kg⁻¹ min⁻¹ 的速率输注后,该肽段使葡萄糖利用率从 14.3 ± 1.1 mg kg⁻¹ min⁻¹ 显著提升至 21.4 ± 2.9 mg kg⁻¹ min⁻¹,且不伴随胰岛素或胰高血糖素水平的明显变化。在肥胖小鼠模型中,GLP-1(32-36)amide 通过激活棕色脂肪组织中的 UCP-1 和 UCP-3,以及骨骼肌中的 AMPK 信号通路,显著增加基础能量消耗并抑制体重增长。该产品适用于能量代谢调控、脂肪氧化及产热机制的基础研究场景。
GLP-1(32-36)amide 是由胰高血糖素样肽-1(GLP-1)衍生而来的五肽片段,序列为 LVKGR amide。在高血糖钳夹实验中,以 30 pmol kg⁻¹ min⁻¹ 的速率输注后,该肽段使葡萄糖利用率从 14.3 ± 1.1 mg kg⁻¹ min⁻¹ 显著提升至 21.4 ± 2.9 mg kg⁻¹ min⁻¹,且不伴随胰岛素或胰高血糖素水平的明显变化。在肥胖小鼠模型中,GLP-1(32-36)amide 通过激活棕色脂肪组织中的 UCP-1 和 UCP-3,以及骨骼肌中的 AMPK 信号通路,显著增加基础能量消耗并抑制体重增长。该产品适用于能量代谢调控、脂肪氧化及产热机制的基础研究场景。


TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | GLP-1(32-36)amide (LVKGRamide) is a naturally occurring pentapeptide cleavage product derived from the glucoincretin hormone GLP-1. Under hyperglycemic clamp conditions, infusion of the pentapeptide significantly increased whole-body glucose utilization to 21.4 mg kg⁻¹ min⁻¹ compared to 14.3 mg kg⁻¹ min⁻¹ with saline, without altering insulin or glucagon levels. In diet-induced obese mice, the peptide inhibited weight gain, reduced fat mass independent of energy intake, and raised basal energy expenditure alongside increased UCP-1 and UCP-3 expression in brown adipose tissue. This compound is a valuable research tool for investigating non-insulinotropic glucose disposal, fatty acid oxidation via AMPK activation, and energy metabolism pathways in obesity and metabolic disorder models. |
| 体外活性 | GLP-1(32-36)amide (0.1-10 μM; 24 h) retains cell viability and decreases apoptosis against Streptozotocin (STZ; 1 μM) in INS‐1 cells[2]. Cell Viability Assay[2] Cell Line: INS‐1 cells |
| 体内活性 | GLP-1(32-36)amide (1 μmol/kg; i.p. once daily for 21 d) protects islet from damage, inhibits weight gain, and relieves symptoms of polydipsia in diabetic mice[2].GLP-1(32-36)amide (1 μmol/kg; a single i.p.) slightly reduces the mean glucose lever at 30 min after the challenge of glucose in normal mice[2].GLP-1(32-36)amide (50-70 nmol/kg/d; infusion for 12-16 weeks) prevents the development of diet-induced obesity and hepatic steatosis in high fat-fed mice[3]. Animal Model: Male KM mice (6-8 weeks; 18-22 g) injected with STZ[2] |
| 分子量 | 570.74 |
| 分子式 | C25H50N10O5 |
| CAS No. | 1417302-71-6 |
| Smiles | CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O |
| Sequence | Leu-Val-Lys-Gly-Arg-NH₂ |
| Sequence Short | LVKGR |
| 存储 | Keep away from moisture, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 250 mg/mL (438.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.78 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多